RPS6KB1 and colorectal carcinoma: These findings add protein- and phosphosite-level evidence linking TP53 loss to an immune-suppressive metabolic state and support biomarker-guided evaluation of mTOR kinase (TORC1/2) inhibition, which more fully suppresses 4E-BP/S6K phosphorylation, combined with PD-1/PD-L1 (± CTLA-4) blockade in TP53-deficient MSS CRC.